Researchers at the University of Pennsylvania discovered that intermittent use of GLP-1 drugs like semaglutide in mice led to weight gain and fat accumulation. The study from Penn's Leung Lab showed reduced drug effectiveness after cycling on and off the medication. About one in eight adults use…
GLP-1 medications rank among the top choices for weight loss today. A new study from the University of Pennsylvania indicates that using these drugs intermittently might produce results opposite to expectations. Consistency proves essential for their success.
The research highlights how stopping and restarting GLP-1 treatments can diminish benefits. Scientists observed this in animal models over time. The findings stress the need for steady use to avoid setbacks.
Teams in Penn's Leung Lab conducted tests on mice across a four-month span. They alternated semaglutide administration, the key component in drugs like Ozempic. Both groups began on the medication, then paused it before resuming twice.
"We started with both groups on the Sema, take them off, put them back on, put them back on. We did that twice," explained research specialist Anna Son. The intermittent group gained weight, specifically fat. Even after a consistent 62-day second cycle, the drug showed less impact.
Interruption appeared to weaken the medication's potency. Mice failed to lose weight as hoped after restarts. This pattern emerged clearly in the controlled setting.
GLP-1 drugs enjoy widespread adoption for weight management. Roughly one in eight adults rely on them for this purpose. Demand continues to grow amid obesity concerns.
Yet maintaining use poses difficulties. More than half of users quit within two years. Many later resume, mirroring the cycles tested in mice.
This stop-start behavior affects outcomes. Researchers link it to real-world patterns among patients. Steady adherence remains a significant obstacle.
"It's because the people we know who are on GLP-1 constantly discontinue and restart their medication," noted Emmanuel Rapp, a graduate student in Penn's Leung Lab. The study suggests therapeutic resistance develops. This makes the drug less effective over time.
Such resistance explains diminished results after breaks. The Penn work provides evidence from animal trials. It aligns with observations in human users.
The research appeared on Friday,
, at 3:20AM from Philadelphia. It builds on prior Penn efforts, including AI analysis of GLP-1 side effects. Additional coverage explains how these drugs target obesity in body and brain.
---
Looking for high-purity research peptides? Browse our catalog for HPLC-verified compounds.
| Compound | Purity | Size | Price |
|---|---|---|---|
| Semaglutide 10mg /product/semaglutide-10mg | ≥98% | 10mg | $49.00 |
Browse Full Catalog → /catalog
Peptides referenced: Semaglutide, GLP-1.
Related reading: Cell-Penetrating Peptides Aid Intracellular Delivery, Figure 2: Antimicrobial Peptide Axes Governing Amyloid Cross-Seeding, Broad Opportunities in Polypeptide Drug Development, GnRH3 Neuropeptide Regulates PGC Proliferation and Sex Differentiation in Zebrafish.